LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 39 of 66
Next
>>
>
951 to 975 of 1647 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Palbociclib	180619_MC_11	14013	0.0201	54	229	13	19	Palbociclib	0.00998	treatment	72	2	MCF10A-GM_6	283	0.0198	635.9	71.1	15071	356.7	0.0231	-0.00328	0.9684
Palbociclib	180619_MC_12	14839	0.0280	112	307	3	19	Palbociclib	0.00998	treatment	72	2	MCF10A-GM_7	419	0.0275	635.9	71.1	15071	356.7	0.0231	0.00439	0.9932
Palbociclib	180619_MC_12	15564	0.0307	126	356	13	8	Palbociclib	0.00998	treatment	72	2	MCF10A-GM_8	482	0.0300	635.9	71.1	15071	356.7	0.0231	0.00696	1.0141
Palbociclib	180619_MC_12	15341	0.0245	78	299	14	11	Palbociclib	0.00998	treatment	72	2	MCF10A-GM_9	377	0.0240	635.9	71.1	15071	356.7	0.0231	0.00091	1.0078
Palbociclib	180619_MC_10	10616	0.0223	68	170	9	7	Palbociclib	0.031603333	treatment	72	2	MCF10A-GM_1	238	0.0219	635.9	71.1	15071	356.7	0.0231	-0.00115	0.8523
Palbociclib	180619_MC_10	9244	0.0198	57	127	9	16	Palbociclib	0.031603333	treatment	72	2	MCF10A-GM_2	184	0.0195	635.9	71.1	15071	356.7	0.0231	-0.00356	0.7970
Palbociclib	180619_MC_10	13608	0.0190	53	207	11	15	Palbociclib	0.031603333	treatment	72	2	MCF10A-GM_3	260	0.0187	635.9	71.1	15071	356.7	0.0231	-0.00433	0.9558
Palbociclib	180619_MC_11	12262	0.0218	66	203	3	10	Palbociclib	0.031603333	treatment	72	2	MCF10A-GM_4	269	0.0215	635.9	71.1	15071	356.7	0.0231	-0.00161	0.9117
Palbociclib	180619_MC_11	13595	0.0279	113	269	3	15	Palbociclib	0.031603333	treatment	72	2	MCF10A-GM_5	382	0.0273	635.9	71.1	15071	356.7	0.0231	0.00426	0.9554
Palbociclib	180619_MC_11	12846	0.0247	79	240	5	3	Palbociclib	0.031603333	treatment	72	2	MCF10A-GM_6	319	0.0242	635.9	71.1	15071	356.7	0.0231	0.00116	0.9313
Palbociclib	180619_MC_12	11875	0.0216	90	168	4	19	Palbociclib	0.031603333	treatment	72	2	MCF10A-GM_7	258	0.0213	635.9	71.1	15071	356.7	0.0231	-0.00181	0.8983
Palbociclib	180619_MC_12	15293	0.0222	105	237	10	16	Palbociclib	0.031603333	treatment	72	2	MCF10A-GM_8	342	0.0219	635.9	71.1	15071	356.7	0.0231	-0.00120	1.0064
Palbociclib	180619_MC_12	14879	0.0240	123	237	11	3	Palbociclib	0.031603333	treatment	72	2	MCF10A-GM_9	360	0.0236	635.9	71.1	15071	356.7	0.0231	0.00055	0.9944
Palbociclib	180619_MC_10	6729	0.0232	76	82	5	12	Palbociclib	0.099799997	treatment	72	2	MCF10A-GM_1	158	0.0229	635.9	71.1	15071	356.7	0.0231	-0.00013	0.6763
Palbociclib	180619_MC_10	7683	0.0168	54	76	8	6	Palbociclib	0.099799997	treatment	72	2	MCF10A-GM_2	130	0.0166	635.9	71.1	15071	356.7	0.0231	-0.00644	0.7257
Palbociclib	180619_MC_10	10757	0.0187	59	143	14	11	Palbociclib	0.099799997	treatment	72	2	MCF10A-GM_3	202	0.0184	635.9	71.1	15071	356.7	0.0231	-0.00464	0.8576
Palbociclib	180619_MC_11	9977	0.0220	77	144	4	11	Palbociclib	0.099799997	treatment	72	2	MCF10A-GM_4	221	0.0217	635.9	71.1	15071	356.7	0.0231	-0.00140	0.8273
Palbociclib	180619_MC_11	11160	0.0209	52	182	5	6	Palbociclib	0.099799997	treatment	72	2	MCF10A-GM_5	234	0.0205	635.9	71.1	15071	356.7	0.0231	-0.00254	0.8727
Palbociclib	180619_MC_11	12084	0.0199	61	181	13	11	Palbociclib	0.099799997	treatment	72	2	MCF10A-GM_6	242	0.0196	635.9	71.1	15071	356.7	0.0231	-0.00344	0.9056
Palbociclib	180619_MC_12	14165	0.0227	116	208	8	17	Palbociclib	0.099799997	treatment	72	2	MCF10A-GM_7	324	0.0224	635.9	71.1	15071	356.7	0.0231	-0.00071	0.9730
Palbociclib	180619_MC_12	12909	0.0206	77	190	12	3	Palbociclib	0.099799997	treatment	72	2	MCF10A-GM_8	267	0.0203	635.9	71.1	15071	356.7	0.0231	-0.00281	0.9333
Palbociclib	180619_MC_12	12706	0.0180	66	164	12	5	Palbociclib	0.099799997	treatment	72	2	MCF10A-GM_9	230	0.0178	635.9	71.1	15071	356.7	0.0231	-0.00529	0.9266
Palbociclib	180619_MC_10	2907	0.0534	124	38	3	11	Palbociclib	0.332666627	treatment	72	2	MCF10A-GM_1	162	0.0528	635.9	71.1	15071	356.7	0.0231	0.02971	0.3949
Palbociclib	180619_MC_10	3194	0.0376	81	42	4	21	Palbociclib	0.332666627	treatment	72	2	MCF10A-GM_2	123	0.0371	635.9	71.1	15071	356.7	0.0231	0.01401	0.4239
Palbociclib	180619_MC_10	4889	0.0246	73	49	9	18	Palbociclib	0.332666627	treatment	72	2	MCF10A-GM_3	122	0.0243	635.9	71.1	15071	356.7	0.0231	0.00127	0.5630

|<
<<
Previous
Page 39 of 66
Next
>>
>
951 to 975 of 1647 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)